Page last updated: 2024-12-09

erythronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

erythronic acid : The erythro-isomer of 2,3,4-trihydroxybutanoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

D-erythronic acid : An erythronic acid in which the stereocentres at positions 2 and 3 both have R-configuration (the D-enantiomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

erythronate : A hydroxy monocarboxylic acid anion obtained by deprotonation of the carboxy group of any erythronic acid; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2781043
CHEBI ID37655
SCHEMBL ID6437643
MeSH IDM0335734

Synonyms (22)

Synonym
(2r,3r)-2,3,4-trihydroxybutanoic acid
CHEBI:37655
d-erythronic acid
79C790F8-6EFC-47F0-B7ED-DFA0645BF900
erythronic acid
2,3,4-trihydroxybutanoate
butanoic acid, 2,3,4-trihydroxy-, (r*,r*)-
(r*,r*)-2,3,4-trihydroxybutanoic acid
eax ,
SCHEMBL6437643
488-16-4
(r*,r*)-2,3,4-trihydroxy-butanoate
erythro-2,3,4-trihydroxybutyrate
(r*,r*)-2,3,4-trihydroxy-butanoic acid
erythronate
JPIJQSOTBSSVTP-PWNYCUMCSA-N
C21593
Q27117218
(2r,3r)-2,3,4-trihydroxybutanoicacid
EN300-100615
HY-113048
CS-0059433

Research Excerpts

Overview

Erythronic acid is a novel and major hallmark in TALDO deficiency.

ExcerptReferenceRelevance
"Erythronic acid is a novel and major hallmark in TALDO deficiency. "( Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency.
de Lonlay, P; Engelke, UF; Jakobs, C; Kluijtmans, LA; Mochel, F; Morava, E; Perl, A; Rabier, D; Valayannopoulos, V; Verhoeven-Duif, NM; Wamelink, MM; Wevers, RA; Zijlstra, FS, 2010
)
2.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
erythronic acidThe erythro-isomer of 2,3,4-trihydroxybutanoic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (21.05)18.7374
1990's1 (5.26)18.2507
2000's6 (31.58)29.6817
2010's6 (31.58)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.78 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]